Herantis Announces New Program to Develop Non-Invasive CDNF for Parkinson’s Treatment

Herantis Announces New Program to Develop Non-Invasive CDNF for Parkinson’s Treatment
Herantis Pharma is launching a development program for non-invasive cerebral dopamine neurotrophic factor (CDNF) as a treatment candidate for patients with Parkinson’s disease, the company recently announced. Currently, the investigational treatment needs to be administered directly into the brain using an implanted delivery system suited for Parkinson’s patients. Under the new program, Herantis will seek new methods of delivering the therapy to ... read more
Source: Parkinson’s News TodayPublished on 2018-07-10By Jose Marques Lopes, PhD